SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03589222 |
|
Recruitment Status :
Recruiting
First Posted : July 17, 2018
Last Update Posted : July 27, 2018
|
Sponsor:
PETHEMA Foundation
Information provided by (Responsible Party):
PETHEMA Foundation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2019 |
| Estimated Study Completion Date : | June 2022 |